

Resource Summary Report

Generated by [kravitz2](#) on Aug 14, 2026

PerCP/Cyanine5.5 anti-mouse CD3

RRID:AB_1595492

Type: Antibody

Proper Citation

BioLegend Cat# 100218, RRID:AB_1595492

Antibody Information

URL: http://antibodyregistry.org/AB_1595492

Proper Citation: BioLegend Cat# 100218, RRID:AB_1595492

Target Antigen: CD3

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PerCP/Cyanine5.5 anti-mouse CD3

Description: This monoclonal targets CD3

Target Organism: mouse

Clone ID: Clone 17A2

Antibody ID: AB_1595492

Vendor: BioLegend

Catalog Number: 100218

Alternative Catalog Numbers: 100217

Record Creation Time: 20250819T220327+0000

Record Last Update: 20250820T005759+0000

Ratings and Alerts

No rating or validation information has been found for PerCP/Cyanine5.5 anti-mouse CD3.

No alerts have been found for PerCP/Cyanine5.5 anti-mouse CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 72 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Zhang Y, et al. (2026) Engineered probiotics recruit CAR macrophages and establish immune memory to eradicate heterogeneous glioblastoma in mice. *Cell host & microbe*, 34(2), 212.

Pan J, et al. (2026) A senescent tumor cell-derived nanovesicle directly primes splenic T cells to potentiate cancer radiotherapy. *Cell reports. Medicine*, 7(4), 102709.

Zhou P, et al. (2026) Targeting senescent EGR1+ B cells enhances immunotherapy efficacy in esophageal squamous cell carcinoma. *Cell reports. Medicine*, 102532.

Han J, et al. (2026) A chemical agonist and the Golgi-resident lipid PI4P activate STING by inducing transmembrane helix rearrangement. *Immunity*, 59(1), 34.

Len-Tayon K, et al. (2026) Impaired vitamin D signaling reveals neutrophils as key drivers of prostate cancer dissemination. *EMBO molecular medicine*, 18(5), 1967.

Zhang J, et al. (2026) RNA exonuclease REXO4 resolves m6A-marked R-loops and suppresses anti-tumor immunity. *Molecular cell*.

Guo J, et al. (2026) Immunoglobulin A-producing cells mediate the clinical benefits of metformin via interleukin-10. *Cell reports*, 45(2), 116919.

Guo J, et al. (2026) VSIG4 Restricts Hepatocellular Carcinoma Control by Suppressing Tumor-Specific CD8+ T-cell Immunity in the Tumor Microenvironment. *Cancer immunology research*, 14(5), 718.

Zheng Z, et al. (2026) In vivo CAR-Tfh cell reprogramming restores tolerance in a mouse model of autoimmune hepatitis. *Cell stem cell*, 33(4), 589.

Feng F, et al. (2026) Synthetic M13 phage engagers expand CAR-T cell antigen recognition to overcome tumor heterogeneity. *Trends in biotechnology*, 44(7), 1987.

Zhang T, et al. (2026) Chemically Engineered *L. reuteri* Delivering ??PD-L1 and Gallium Ions via Metal-Phenolic Networks Potentiate Anti-Tumor Immunity and Ferroptosis. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(31), e21638.

Liu X, et al. (2026) Distinct Inflammatory Cytotoxic T Lymphocyte Populations Mediate PD-1 Blockade-Induced Immune-Related Adverse Events in Multiple Organs. *Cancer research*, 86(15), 3720.

Bockman A, et al. (2026) Intratumoral Regulatory T cell Ablation Mediates Tumor Control Systemically without Autoimmunity. *Cancer research*.

Qiao S, et al. (2026) Microbiota utilization of intestinal amino acids modulates cancer progression and anticancer immunity. *Cell host & microbe*, 34(1), 18.

Yang Z, et al. (2025) A mosaic H3 subtype live attenuated influenza vaccine elicits broad immune responses to influenza A viruses. *Vaccine*, 65, 127776.

Yeat NY, et al. (2025) Bro1 proteins determine tumor immune evasion and metastasis by controlling secretion or degradation of multivesicular bodies. *Developmental cell*, 60(15), 2114.

Wang Y, et al. (2025) Activation of stimulator of interferon genes (STING) and inhibition of vascular endothelial growth factor receptor (VEGFR) by telatinib induce antitumor activity. *The Journal of biological chemistry*, 111038.

Li T, et al. (2025) Non-canonical PRC1.1 licenses transcriptional response to enable Treg plasticity in immune adaptation. *Molecular cell*, 85(13), 2517.

Niu D, et al. (2025) Local delivery of IL-15 and anti-PD-L1 nanobody by in vitro-transcribed circILNb elicits superior antitumor immunity in cold tumors. *Cell reports. Medicine*, 6(10), 102413.

Stomper J, et al. (2025) Sex differences in DNMT3A-mutant clonal hematopoiesis and the effects of estrogen. *Cell reports*, 44(4), 115494.